GSK Strikes $3.06 Billion Shingles Vaccine Deal With China's Zhifei -- Update
09 Outubro 2023 - 7:16AM
Dow Jones News
By Michael Susin
GSK said that Chongqing Zhifei Biological Products has agreed to
purchase the company's shingles vaccine Shingrix under an exclusive
agreement in a deal valued at 2.5 billion pounds ($3.06
billion).
The British pharmaceutical giant on Monday said that Zhifei will
have exclusive rights to import and distribute Shingrix in China
for an initial three-year period starting January 1, with the
option of an extension.
The company said that volumes are expected to be phased over the
period as demand is anticipated to accelerate steadily.
"The partnership supports and accelerates GSK's commitment to
double global Shingrix sales, reaching more than GBP4 billion by
2026," it added.
The deal will significantly extend the availability of the
vaccine to healthcare professionals and over 30,000 points of
vaccination, it said.
Zhifei is the largest Chinese vaccine company by revenue, GSK
said.
The partnership will also support potential future
co-development and commercialization of GSK's respiratory syncytial
virus vaccine Arexvy in the country. Arexvy is currently not
approved in China.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
October 09, 2023 06:01 ET (10:01 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024